Cleo Diagnostics Ltd (COV) — Strategic Asset Allocation Index
Cleo Diagnostics Ltd (COV) has a Strategic Asset Allocation Index of 0.3% as of December 2025. Strategic assets (PP&E of AU$27.73K plus long-term investments of AU$-) total AU$27.73K, measured against net assets of AU$8.83 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Cleo Diagnostics Ltd Strategic Asset Allocation Index (2024–2025)
This chart shows how Cleo Diagnostics Ltd's Strategic Asset Allocation Index has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the index stands at 0.3%, representing strategic assets of AU$27.73K against net assets of AU$8.83 Million AUD. Explore cash efficiency ratio of Cleo Diagnostics Ltd to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Cleo Diagnostics Ltd (2024–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Cleo Diagnostics Ltd from 2024 to 2025, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see COV market cap overview.
| Year | SAAI | Strategic Assets (AUD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 0.6% | AU$32.59K | AU$32.59K | AU$- | AU$5.83 Million | ▲ +0.2 pp |
| 2024 | 0.3% | AU$31.95K | AU$31.95K | AU$- | AU$9.39 Million | — |